Study | Country | Study design | Duration | Follow-up | Treatment groups | APACHE II score | Patients | Intervention | ||
---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  |  |  |  | Number | Age, years | Males/Females |  |
Prakash et al. [22], 2008 | India | RCTs | _ | 7 days | Ranitidine | 14.21 ± 5.44 | 25 | 35.1 ± 14.1 | 19/6 | Ranitidine 50 mg, IV, every 6 hours |
 |  |  |  |  | Sucralfate | 13.34 ± 6.03 | 25 | 27.5 ± 16.6 | 13/12 | Sucralfate 1 g, every 6 hours |
Kantorova et al. [23], 2004 | Czech Republic | RCTs | Feb. 2000-June 2002 | Until discharge or death | Famotidine | 19.1 ± 9.3 | 71 | 47.0 ± 17 | 44/27 | Famotidine 40 mg, IV, every 12 hours |
 |  |  |  |  | Sucralfate | 18.8 ± 8.1 | 69 | 51.0 ± 18 | 50/19 | Sucralfate 1 g, every 6 hours |
Darlong et al. [24], 2003 | India | RCTs | _ | _ | Ranitidine | _ | 24 | 44.0+18.5 | 11/13 | Ranitidine 50 mg, IV, every 8 hours |
 |  |  |  |  | Sucralfate |  | 21 | 39.5+15.2 | 14/7 | Sucralfate 1 g, every 8 hours |
Cook et al. [16], 1998 | Canada | Multicenter RCTs | Oct. 1992-May 1996 | Until discharge or death | Ranitidine | 24.7 ± 7.1 | 596 | 58.8 ± 18.1 | 369/227 | Ranitidine 50 mg, IV, every 8 hours |
 |  |  |  |  | Sucralfate | 24.6 ± 7.3 | 604 | 58.7 ± 18.7 | 354/250 | Sucralfate 1 g, every 6 hours |
Thomason et al. [25], 1996 | USA | RCTs | Nov. 1990-May 1994 | 27.3 days | Ranitidine | 17.0 | 136 | 31.0 | _ | Ranitidine 150 mg/day, continuous IV |
 |  |  |  |  | Sucralfate | 19.0 | 140 | 27.7 | _ | Sucralfate 1 g, every 6 hours |
Prod'hom et al. [26], 1994 | Switzerland | RCTs | Jan. 1989-Jan. 1991 | _ | Ranitidine | 16.8 ± 8.6 | 80 | 52.2 ± 18.1 | 54/26 | Ranitidine 150 mg/day, continuous IV |
 |  |  |  | _ | Sucralfate | 17.2 ± 8.6 | 83 | 46.4 ± 17.5 | 56/27 | Sucralfate 1 g, every 4 hours |
Pickworth et al. [27], 1993 | USA | RCTs | Jan. 1989-Aug. 1991 | Until discharge or death | Ranitidine | 18.1 ± 6.5 | 44 | 27.3 | 60/23 | Ranitidine 50 mg, IV, every 6 hours |
 |  |  |  |  | Sucralfate |  | 39 | 26.8 |  | Sucralfate 1 g, every 6 hours |
Ruiz-Santana et al. [28], 1991 | Spain | RCTs | Dec. 1998-Jan. 1990 | Until discharge or death | Ranitidine | 15 ± 5 | 19 | 39.0 ± 17 | 14/5 | Ranitidine 50 mg, IV, every 6 hours |
 |  |  |  |  | Sucralfate |  | 24 | 37.0 ± 18 | 20/4 | Sucralfate 1 g, every 4 hours |
Eddleston et al. [29], 1991 | UK | RCTs | _ | _ | Ranitidine | 12.4 ± 1.5 | 30 | 54.1 ± 3.1 | 17/13 | Ranitidine 50 mg, IV, every 6 hours |
 |  |  | _ | _ | Sucralfate | 11.6 ± 1.3 | 30 | 44.3 ± 3.5 | 21/9 | Sucralfate 1 g, every 6 hours |
Laggner et al. [30], 1989 | Austria | RCTs | _ | Until discharge or death | Ranitidine | _ | 16 | 60 ± 15 | 7/9 | Ranitidine 50 mg, IV, every 4 hours |
 |  |  | _ |  | Sucralfate | _ | 16 | 47 ± 19 | 11/5 | Sucralfate 1 g, every 4 hoursa |